The Chilled Future of RNA Therapeutics Filling & Freezing Application

Fluid Management Process for Messenger RNA, Plasmid DNA and Viral Vectors

Traditional and rigid manufacturing processes are not suited for advanced therapies. With novel therapies pushing limits in biotechnology, the life science industry needs to keep up with adequate process solutions around the commercialization of these specific therapies.

While SARS-CoV-2 has definitely boosted the acceptance of mRNA in vaccines, there is an infinite number of RNA vaccines and therapeutics to address other – as of yet unmet – medical needs. And at the same time as biotech and biopharma companies are continuously advancing novel treatments, solution providers are driving process optimization in order to increase efficiency and meet the needs of these new therapies.